Stem-cell treatments prolong OS for blast-phase/accelerated-phase myeloproliferative neoplasms


Patients with Philadelphia chromosome-negative accelerated- or blast-phase myeloproliferative neoplasms who received allogeneic hematopoietic stem cells had a longer median overall survival (OS) than those who did not, according to a study presented at the ASH Annual Meeting. The study, led by Anand Ashwin Patel, MD, at UChicago Medicine, found that the stem-cell therapy resulted in a median OS of 1.82 years for patients who underwent the treatment, compared to the overall median OS of 0.72 years for the entire patient cohort. The study highlights the need for novel management strategies for patients with these neoplasms, even among those eligible for allogeneic hematopoietic stem-cell treatments.

Source link

error: Content is protected !!